Scott & Selber Inc. boosted its position in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 8.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,196 shares of the biopharmaceutical company’s stock after buying an additional 1,163 shares during the quarter. Scott & Selber Inc. owned 0.05% of GW Pharmaceuticals PLC- worth $2,620,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in GWPH. Horan Capital Advisors LLC. purchased a new stake in shares of GW Pharmaceuticals PLC- during the first quarter valued at $25,000. Exane Derivatives purchased a new stake in GW Pharmaceuticals PLC- in the 1st quarter worth about $28,000. TCG Advisors LP purchased a new stake in GW Pharmaceuticals PLC- in the 1st quarter worth about $29,000. Institutional & Family Asset Management LLC purchased a new stake in GW Pharmaceuticals PLC- in the 1st quarter worth about $31,000. Finally, Paragon Capital Management LLC purchased a new stake in GW Pharmaceuticals PLC- in the 1st quarter worth about $34,000. 78.92% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts recently issued reports on GWPH shares. ValuEngine downgraded GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research note on Monday. CIBC raised GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a research note on Tuesday, May 7th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $192.00 price objective for the company in a research note on Monday. Guggenheim reissued a “buy” rating and issued a $222.00 price objective (up from $186.00) on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, May 7th. Finally, JPMorgan Chase & Co. raised GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a research note on Wednesday, May 8th. Two research analysts have rated the stock with a sell rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $209.82.
Shares of GWPH traded up $0.46 during midday trading on Tuesday, reaching $159.84. 19,552 shares of the stock were exchanged, compared to its average volume of 544,465. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00. The business has a 50 day simple moving average of $167.03. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.59 and a current ratio of 8.31. The firm has a market cap of $5.04 billion, a P/E ratio of -15.15 and a beta of 2.25.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.96. The company had revenue of $72.04 million during the quarter, compared to the consensus estimate of $37.28 million. GW Pharmaceuticals PLC- had a negative return on equity of 38.09% and a negative net margin of 101.45%. The business’s quarterly revenue was up 2096.3% on a year-over-year basis. During the same period last year, the business earned ($0.25) EPS. As a group, sell-side analysts predict that GW Pharmaceuticals PLC- will post -4.51 earnings per share for the current year.
In other news, CEO Justin D. Gover sold 202,224 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $15.24, for a total transaction of $3,081,893.76. Following the transaction, the chief executive officer now owns 743,765 shares of the company’s stock, valued at approximately $11,334,978.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Douglas B. Snyder sold 4,968 shares of the stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $14.42, for a total value of $71,638.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 375,732 shares of company stock worth $5,676,404. 3.60% of the stock is currently owned by insiders.
GW Pharmaceuticals PLC- Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Read More: What is a price target?
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.